Analyzing Sucampo Pharmaceuticals (SCMP) and Nexvet Biopharma (NVET)

Sucampo Pharmaceuticals (NASDAQ: SCMP) and Nexvet Biopharma (NASDAQ:NVET) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Institutional and Insider Ownership

How to Become a New Pot Stock Millionaire

67.1% of Sucampo Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.4% of Nexvet Biopharma shares are owned by institutional investors. 4.1% of Sucampo Pharmaceuticals shares are owned by insiders. Comparatively, 37.0% of Nexvet Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Sucampo Pharmaceuticals and Nexvet Biopharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sucampo Pharmaceuticals 0 6 2 0 2.25
Nexvet Biopharma 0 1 0 0 2.00

Sucampo Pharmaceuticals presently has a consensus target price of $22.00, suggesting a potential upside of 21.88%. Nexvet Biopharma has a consensus target price of $6.72, suggesting a potential upside of 0.00%. Given Sucampo Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Sucampo Pharmaceuticals is more favorable than Nexvet Biopharma.

Earnings and Valuation

This table compares Sucampo Pharmaceuticals and Nexvet Biopharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sucampo Pharmaceuticals $230.06 million 3.70 $18.48 million ($3.35) -5.39
Nexvet Biopharma N/A N/A N/A ($1.75) -3.84

Sucampo Pharmaceuticals has higher revenue and earnings than Nexvet Biopharma. Sucampo Pharmaceuticals is trading at a lower price-to-earnings ratio than Nexvet Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sucampo Pharmaceuticals and Nexvet Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sucampo Pharmaceuticals 16.92% 126.04% 11.04%
Nexvet Biopharma N/A -102.72% -89.82%

Summary

Sucampo Pharmaceuticals beats Nexvet Biopharma on 8 of the 11 factors compared between the two stocks.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

About Nexvet Biopharma

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Elementrem  Trading 1.4% Lower  This Week
Elementrem Trading 1.4% Lower This Week
Fastcoin Trading 1% Higher  Over Last Week
Fastcoin Trading 1% Higher Over Last Week
Kadant  Expected to Post Quarterly Sales of $145.40 Million
Kadant Expected to Post Quarterly Sales of $145.40 Million
Zacks: Brokerages Expect GameStop  to Post $0.40 EPS
Zacks: Brokerages Expect GameStop to Post $0.40 EPS
$0.83 Earnings Per Share Expected for Consol Energy  This Quarter
$0.83 Earnings Per Share Expected for Consol Energy This Quarter
IHI  & Intevac  Financial Comparison
IHI & Intevac Financial Comparison


© 2006-2018 Ticker Report. Google+.